DEVELOPMENTAL RESEARCH PROGRAM

DRP 导演：约翰·伦纳德医学博士(WCMC) 联合导演：阿纳斯·尤尼斯(MSK) DRP摘要 发展研究计划(DRP)将确定新的机会来支持医生和 科学家，并鼓励他们利用他们的专业知识在 淋巴瘤。DRP将提供种子资金，以产生和探索新的假设，这些假设可能 随后在淋巴瘤孢子内或通过其他孢子作为完整项目进行扩展和测试- 独立的同行评审的外部赠款支持。孢子DRP的目的是开发翻译 旨在改进诊断和治疗的研究项目，应导致可检验的假设 淋巴瘤。每年，将向所有参与机构分发征求建议书。 选定的提案(每年1-2个)将得到50,000美元孢子预算的支持，并进行匹配 制度保障。资助期限为1年。基于第一年的成就，以及 经教统局审核后，拨款可再延长一年。将使用常规的NIH审查标准 选择项目。来自代表不足的少数族裔和女性申请者的提案将具体 主动要求的。该计划利用了一批拥有有案可查的科学记录的强大调查人员 和所有三个参与机构的卓越基础设施，纪念斯隆·凯特琳癌症中心 (MSK)、威尔-康奈尔医学院(WCMC)和哥伦比亚大学医学中心/Herbert Irving 综合癌症中心。

DRP Director: John Leonard, MD (WCMC) Co-Director: Anas Younes (MSK) DRP SUMMARY The Developmental Research Program (DRP) will identify new opportunities to support physicians and scientists, and encourage them to use their expertise to develop novel translational research ideas in lymphoma. The DRP will provide seed funding to generate and explore new hypotheses that may subsequently be expanded and tested as full project within the Lymphoma SPORE, or through other SPORE- independent peer-reviewed external grant support. The purpose of the SPORE DRP is to develop translational research projects that should result in testable hypotheses aimed at improving the diagnosis and treatment of lymphoma. On an annual basis, a request for proposals will be distributed to all participating institutions. Selected proposals (1-2 annually) will be supported with $50,000 of the SPORE budget with matching institutional support. Funding will be awarded for 1 year. Based on accomplishments during the first year, and review by the EAB, funding may be extended by a second year. Usual NIH review criteria will be used in selection of projects. Proposals from underrepresented minority and female applicants will be specifically solicited. The program takes advantage of a strong group of investigators with documented scientific record and outstanding infrastructure at all three participating Institutions, Memorial Sloan Kettering Cancer Center (MSK), Weill-Cornell Medical College (WCMC) and the Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center.